Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 29, 2019 in Leukemia | 0 comments

In a nutshell

This study evaluated if the intensified postinduction therapy is safe and effective to treat children with standard-risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study concluded that the treatment excellently impacted survival among patients, but further intensifying the therapy might be unnecessary.

Some background

B-ALL is the most common childhood blood cancer. Induction therapy is the first treatment given for this disease. After this therapy, intensification is used to kill any cancer cells left in the body. Intensification improved the survival in children with a high risk (HR) a B-ALL’s return after disease-free periods. However, intensification has several toxic side effects. Whether patients with SR B-ALL truly need this treatment is unclear. Therefore, it is important to balance its benefits against the risks.

Methods & findings

The study examined 5,377 children with SR B-ALL between 2005 and 2010. All of them received an induction therapy comprising 3 drugs – dexamethasone (Decadron), vincristine (Oncovin), and pegaspargase (Oncaspar). They were further divided into 3 groups – SR low, SR average, or SR high, based on the risk of ALL. 

Patients with SR-average disease received either regular intensification (group 1) for 4-weeks or augmented Berlin-Frankfurt-Munster (BFM) treatment for 8-weeks (group 2). Augmented BFM is a stronger version of intensification therapy. Those with SR-high disease also received augmented BFM. 

After 6 years of the treatment, 95.54% of the SR-average patients had survived. 87.8% of patients in group 1 and 89.1% of group 2 were in continuous complete remission after 6 years. 95.8% of patients in group 1 and 95.2% of those in group 2 were alive after 6 years. 

The bottom line

This study concluded that more than 95% of the children with SR B-ALL survived for 6 years after postinduction therapy. The authors suggested that further increase in the therapy’s intensity may not be needed.

The fine print

This study did not compare the treatment with placebos (medicines with no effects). It also made changes in the treatment plan during the research. Additional studies are needed.

Published By :

Journal of clinical oncology

Date :

Dec 11, 2019

Original Title :

Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0331.

click here to get personalized updates